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Abstract
Background: Dyspnea is the most common symptom in acute heart failure (AHF), yet how to best
measure it has not been well defined. Prior studies demonstrate differences in dyspnea improvement
across various measurement scales, yet these studies typically enroll patients well after the emergency
department (ED) phase of management.
Objectives: The aim of this study was to determine predictors of early dyspnea improvement for three
different, commonly used dyspnea scales (i.e., five-point absolute Likert scale, 10-cm visual analog scale
[VAS], or seven-point relative Likert scale).
Methods: This was a post hoc analysis of URGENT Dyspnea, an observational study of 776 patients in 17
countries enrolled within 1 hour of first physician encounter. Inclusion criteria were broad to reflect real-
world clinical practice. Prior literature informed the a priori definition of clinically significant dyspnea
improvement. Resampling-based multivariable models were created to determine patient characteristics
significantly associated with dyspnea improvement.
Results: Of the 524 AHF patients, approximately 40% of patients did not report substantial dyspnea
improvement within the first 6 hours. Baseline characteristics were similar between those who did or did
not improve, although there were differences in history of heart failure, coronary artery disease, and
initial systolic blood pressure. For those who did improve, patient characteristics differed across all three
scales, with the exception of baseline dyspnea severity for the VAS and five-point Likert scale (c-index
ranged from 0.708 to 0.831 for each scale).
Conclusions: Predictors of early dyspnea improvement differ from scale to scale, with the exception of
baseline dyspnea. Attempts to use one scale to capture the entirety of the dyspnea symptom may be
insufficient.
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Signs and symptoms of heart failure promptpatients to seek medical care, with dyspnea asthe most common symptom.1,2 Yet a large pro-
portion of patients discharged from the hospital
remain symptomatic or have little weight loss. Severity
of dyspnea at baseline, as well as failure to adequately
relieve it during hospitalization, have been associated
with worse outcomes.3,4 Thus, improving dyspnea is
important to both patients and physicians and is also
an important target in acute heart failure (AHF) clinical
trials.5
Over 5 years ago, a consensus for standardization of
dyspnea assessments was proposed, yet assessment
scales used today remains largely unchanged.5 Typical
assessments include a visual analog scale (VAS), a Likert
scale, or both.6 Past studies demonstrate that the VAS
better captures changes in dyspnea over time compared
to Likert-type scales and that patient positioning during
measurement (sitting upright vs. supine) affects
responses.5,7,9 Timing of dyspnea assessment is also
important, as earlier treatment is associated with greater
dyspnea relief, although many patients remain symptom-
atic despite early therapeutic intervention.3,4,8–10 Early
dyspnea relief has also been associated with improved
30-day outcomes.11 While the reliability of VAS and Lik-
ert scales is implied by their ease, repeated use, and
ability to track changes over time, their reliability has
not been studied rigorously.5,6,12 Previous studies show
differences in patient responses between Likert and
VAS, suggesting poor interscale reliability.7,9,13 Yet
some of these studies have enrolled patients well after
the initial emergency department (ED) phase of man-
agement, when previous work has demonstrated signifi-
cant dyspnea improvement occurs early.9
Given these differences, we set out to determine pre-
dictors of early dyspnea improvement, according to a
prespecified criterion of improvement for three differ-
ent, commonly used dyspnea scales. Our hypothesis
was that these predictors, as defined by baseline patient
characteristics, would differ by type of scale. If they
converge, then any measurement scale would suffice. If
they diverge, this would suggest that each scale mea-
sures dyspnea differently, or measures different aspects
of the symptom, and a unifying scale or multiple scales
to accurately assess dyspnea are needed. Thus, we con-
ducted a secondary analysis of the URGENT Dyspnea
(Ularitide Global Evaluation in Acute Decompensated
Heart Failure) study9 to compare differences in propor-
tions of responders and patient characteristics between
three different measurement scales to identify early
(6 hours after enrollment) dyspnea improvement.
METHODS
Study Design
The URGENT Dyspnea study design has been previously
described.9,14 Briefly, 776 patients from 35 institutions in
17 countries over a 7-month period (January 2007
through August 2007) were enrolled in an observational
cohort study. The main study was designed to better
understand the association of early standard therapy
with dyspnea relief. Institutional review board or ethics
committee approval was obtained from every site prior
to participation in the URGENT Dyspnea study.
Study Setting and Population
Patients aged 18 years or older with dyspnea secondary
to a presumptive diagnosis of AHF were enrolled within
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1 hour of first physician evaluation. Inclusion criteria
were intentionally kept broad to better reflect “real-
world” conditions, with the understanding that a pro-
portion of dyspneic patients enrolled within 1 hour of
presentation may not have AHF. Patients unable to con-
sent or unable to self-assess dyspnea were excluded.
Patients were treated with standard AHF management
at the discretion of their health care teams; demo-
graphic, clinical, and treatment data were collected. The
study protocol did not provide specific AHF treatment
recommendations. The individual site investigator deter-
mined the final diagnosis of AHF based on full access to
all available clinical data.
Study Protocol
This study was designed to determine predictors of early
dyspnea improvement (“early” defined as baseline to
6 hours), for three distinct dyspnea scales. Thus, three
separate analyses were performed, one for each scale;
only patients with dyspnea improvement per their
respective scale were included in each analysis. Early
dyspnea improvement was defined a priori (see Table 1),
as follows: 1) any one point improvement on a five-point
Likert scale,15 2) a three-point improvement on a 10-cm
VAS (based on prior research demonstrating a change
of 2.1 cm on a 100-mm VAS as clinically significant),15
and 3) moderate or marked improvement in dyspnea on
a seven-point Likert scale (no baseline scores for this
scale).13 Patients with minimal dyspnea at baseline who
could not meet the criteria for improvement were
excluded. Baseline dyspnea was defined as the self-
reported patient score for both the five-point Likert scale
and the VAS, as there was no baseline dyspnea assess-
ment for the seven-point Likert scale because it only
reports change in symptoms. Severity of dyspnea was
assessed by the patient in the upright position, defined
as head of bed at least 60 degrees from horizontal.
Data Analysis
Multivariable models were created to identify baseline
factors associated with dyspnea improvement. To over-
come the well-known shortcomings of many automatic
variable selection methods (i.e., instability, sensitivity to
outliers, or lack of reproducibility), we have used a sim-
plified version of a highly cited and widely employed
resampling-based machine learning ensemble method
called bagging.16 This model-averaging method avoids
model overfitting, improves model stability and accu-
racy, and provides better protection against outliers
and/or extreme observations. Therefore, bagging pro-
vides a principled and robust multivariable model-build-
ing strategy for dyspnea improvement.
Three separate models were created, one for each
method of dyspnea assessment. Comparisons were not
made between models, as this would imply attempts to
find which model had the best fit to the same data. Pre-
vious analyses have described the effect of early therapy
on dyspnea relief.9 Rather, three separate models were
created using the technique below for each model. Each
model was created from the unique data set derived
using the simplified bagging methodology.
For each dyspnea improvement definition, a two-stage
process was created: first, the original data set was re-
sampled (with replacement) 50,000 times. Within each
such sample, stepwise variable selection with 0.05/0.1
entry/exit criteria occurred in the logistic regression
model for dyspnea improvement. In a voting-like fash-
ion, the list of factors (predictors) significant at two-sided
5% level across the 50,000 resamples was created. In
stage two, the short list of predictors that were signifi-
cant in at least 10,000 of the 50,000 resamples was com-
piled. Only these predictors were then included in the
final logistic regression model, which was created based
solely on the original data. Results are shown in Table 2.
A full list of covariates considered for inclusion is pro-
vided in Data Supplement S1 (available as supporting
information in the online version of this paper); elements
including demographics, presenting signs and symp-
toms, diagnostic data, and medical history were consid-
ered. We were unable to include site of enrollment due
to small numbers of patients from some sites, inducing
instability in the models. The full list of enrollment by site
is included in Data Supplement S2 (available as support-
ing information in the online version of this paper). Spe-
cifically in regard to troponin testing, as multiple
countries using multiple troponin I assays were included,
we used a single arbitrary cut point of 0.04 across all
patients. Model performance was quantified using the
area under the receiver’s operating characteristics curve
(c-index). Model appropriateness based on raw and stan-
dardized Pearson and deviance residuals indicated no
discernible influential data points, multicollinearity prob-
Table 1
Dyspnea Assessment Instruments and Definitions of Improvement
Type of Scale Scale Intervals
Definition of Clinically Significant
Improvement
Five-point
Likert scale
1 = not short of breath, 2 = mildly short of breath, 3 = moderately
short of breath, 4 = severely short of breath, 5 = very severely
short of breath.
≥1-point change
10-cm VAS 1-cm increments, anchored by “I am not breathless at all” to
“I am the most breathless I have ever been.”
≥3-cm change
Seven-point
Likert scale
Patients were asked to compare how they felt when they
were first asked regarding dyspnea. Scores ranged from
“Markedly worse, moderately worse, mildly worse,
no change, mildly better, moderately better, markedly better.”
Only patients who responded moderately
or markedly improved
VAS = visual analog scale.
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lems, or nonlinear covariate functional forms. Statistical
significance was established at the two-sided 5% alpha
level and no adjustments for multiplicity were made.
RESULTS
Of the 776 patients enrolled within 1 hour of first physi-
cian assessment, 524 had AHF at the 6-hour evaluation,
79 did not have AHF, and in 173 the diagnosis was
uncertain. Differences in baseline characteristics
between those with AHF, those without AHF, and those
with indeterminate diagnoses have been previously
reported.9 Figure 1 describes the patient flow for each
of the separate dyspnea assessments, reporting those
patients able to improve per our prespecified criteria.
Overall, the majority of patients reported improve-
ment on at least one scale by 6 hours. However, a
sizable number of patients did not improve. Specifically,
per the five-point Likert scale, 34.1% of patients (132 of
387) did not have a one-point improvement by 6 hours;
by the seven-point Likert scale, 38.7% of patients (184 of
476) did not have moderate or marked improvement;
and by the VAS, 57.2% of patients (178 of 311) did not
have a three-point improvement.
Table 2
Patient Characteristics Stratified by Five-point Likert Scale
Change
Variable
Not
Improved
(n = 142)
Improved
(n = 299) p-value
Age (yr),
mean (SD)
66.1  15.5 68.8  14.0 0.07
Sex, female 63 (44) 134 (45) 0.93
Race 0.012
Black 34 (24) 36 (12)
White 107 (75) 258 (86)
Heart failure history 0.002
Chronic heart
failure
102 (73) 166 (57)
New onset
heart failure
38 (27) 125 (43)
Most recent known
LVEF, median
(IQR) (n = 227)
38.0 (10–75) 40.0 (10–80) 0.33
Past medical history
CAD 74 (52) 112 (37) 0.004
Prior MI 37 (26) 72 (24) 0.65
Primary
cardiomyopathy
28 (20) 30 (10) 0.005
Obesity 37 (26) 75 (25) 0.83
Peripheral vascular
disease
9 (6) 30 (10) 0.20
Asthma/COPD 29 (20) 46 (15) 0.19
Diabetes
Insulin-dependent 27 (19) 43 (14) 0.21
Non–insulin-
dependent
27 (19) 61 (20) 0.73
Renal insufficiency 38 (27) 78 (26) 0.88
Anemia
(Hb < 12 g/dL)
28 (20) 36 (12) 0.032
Hypertension 103 (73) 227 (76) 0.44
Prehospital treatment 0.015
Yes 69 (49) 178 (60)
No 63 (44) 91 (30)
Unknown 10 (7) 30 (10)
Signs and symptoms prior to triage
Onset of dyspnea
before triage
0.11
1 to 3 days 26 (18) 45 (15)
3 to 5 days 13 (9) 28 (9)
Past 24 hours 41 (29) 123 (41)
> 5 days 61 (43) 99 (33)
Weight gain 49 (35) 91 (30) 0.39
Fatigue 102 (72) 167 (56) 0.001
No preceding
signs
17 (12) 57 (19) 0.06
Initial vital signs, mean (SD)
Systolic BP
(mm Hg)
137.3  33.7 146.7  33.9 0.007
Diastolic BP
(mm Hg)
78.7  19.6 82.4  19.1 0.06
Heart rate
(beats/min)
89.4  22.4 92.4  24.6 0.21
Respiratory rate
(breaths/min)
21.5  7.0 23.0  7.0 0.041
Oxygen saturation 94.3  5.3 92.3  5.9 0.002
Physical examination findings
Abnormal heart
sounds (e.g.,
murmur, gallop)
48 (34) 71 (24) 0.026
Jugular venous
distention
70 (49) 117 (39) 0.044
Rales 90 (63) 204 (68) 0.31
Wheezing 22 (15) 38 (13) 0.43
Peripheral edema 85 (60) 147 (49) 0.036
Other signs: none
of the above
10 (7) 36 (12) 0.11
Table 2
Continued
Variable
Not
Improved
(n = 142)
Improved
(n = 299) p-value
Laboratory results, mean (SD)
Serum sodium
(mmol/L)
137.1  12.5 135.9  16.5 0.44
Serum potassium 4.0  0.9 3.9  0.9 0.16
Creatinine 1.5  1.4 1.5  1.1 0.58
Urea 43.9  51.2 27.2  35.5 <0.001
BNP, median
(IQR) (n = 98)
866.5
(40–5,019)
938.5
(61–4,357)
0.65
NTpro BNP,
median (IQR)
(n = 89)
7,281
(902–34,019)
6,302.5
(395–30,000)
0.27
Troponin > 0.04
ng/mL (n = 171)
42 (30) 129 (43) 0.006
CXR and ECG Results
CXR
Normal 4 (3) 5 (2) 0.43
Interstitial edema 77 (54) 122 (41) 0.008
Pulmonary edema 18 (13) 60 (20) 0.06
First ECG
Normal 10 (7) 21 (7) 0.99
Sinus rhythm 76 (54) 174 (58) 0.35
Baseline medications
Beta-blockers 88 (62) 143 (48) 0.005
ACE inhibitors 74 (52) 139 (46) 0.27
Angiotension II
receptor blockers
16 (11) 38 (13) 0.67
Aldosterone
antagonists
26 (18) 26 (9) 0.003
Diuretics 105 (74) 183 (61) 0.009
Data are reported as n (%) unless otherwise noted.
ACE = angiotensin-converting enzyme; BNP = brain natri-
uretic peptide; BP = blood pressure; CAD = coronary artery
disease; COPD = congestive obstructive pulmonary disease;
ECG = electrocardiogram; Hb = hemoglobin; LVEF = left ven-
tricular ejection fraction; MI = myocardial infarction;
NTproBNP = N-terminal pro-brain natriuretic peptide.
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Baseline characteristics are seen in Table 2. The five-
point Likert scale was chosen for baseline character-
istics in Table 2 as it had the best discrimination by
c-statistic. Patients with dyspnea improvement were
similar to patients who did not improve with the follow-
ing exceptions: improved patients were more likely to
have new-onset HF, higher systolic blood pressures,
and troponin I levels > 0.04 ng/mL. They were also less
likely to be chronically treated with beta-blocker ther-
apy, diuretics, and aldosterone antagonists. Table 3
shows the treatments patients received within the first
6 hours of management.
Three separate multivariable models identifying patient
characteristics associated with dyspnea improvement are
shown in Tables 4A–4C, representing each method of
dyspnea assessment. The discrimination ability of each
model was relatively high (c-index = 0.708 to 0.831).
Severity of dyspnea at baseline was common across all
three models as a predictor of improvement; the less
severe the dyspnea, the less likely patients would report
improvement. No other clinical, laboratory, or treatment
factors were common to all three models. Overall, there
were more differences in patient characteristics associated
with dyspnea improvement per each model of dyspnea
assessment than there were similarities.
DISCUSSION
In this observational study of AHF patients enrolled
within 1 hour of first physician contact, most patients
report dyspnea improvement within 6 hours of initial
management, irrespective of the assessment scale used.
However, a sizable proportion of patients did not report
improvement according to our predetermined defini-
tions of clinical significance. For those who did improve,
substantial variation in patient characteristics associated
with dyspnea improvement between measurement
scales were observed. These differences support previ-
ous studies suggesting different scales measure dyspnea
differently.7,9 No patient characteristic was associated
with greater or lesser dyspnea improvement in all three
of our models (Figure 2). Severity of dyspnea at baseline
was associated with improvement for both the five-point
Likert and the VAS, although only for those patients
with the most severe dyspnea as measured by the Likert
scale. Of note, the seven-point Likert scale did not have
a baseline dyspnea assessment.
776 patients enrolled
79 without acute heart 
failure at 6 hours
173 diagnosis of acute 
heart failure unknown
524 with acute heart failure at 6
hours
Model 1: 
Five point Likert scale
387 with mild to very 
severe baseline 
dyspnea on five point 
Likert scale in sitting 
position and 6 hr
dyspnea information
Model 2: 
VAS
311 with baseline 
dyspnea score of 3 or 
more on the visual 
analog scale and 6 hr
dyspnea score available 
Model 3: 
Seven point Likert scale
476 with mild to very 
severe baseline 
dyspnea on seven point 
Likert scale in sitting 
position and 6 hr
dyspnea information
Figure 1. Study flow diagram of the patient groups obtained
using the hour 6 dyspnea symptoms improvement definitions.
AHF = acute heart failure; Dx = diagnosis.
Table 3
Initial Treatment Within the First 6 Hours
Variable
Not Improved
(n = 142)
Improved
(n = 299) p-value
CPAP at 6 hours 0.13
Yes 2 (1) 12 (4)
No 134 (99) 262 (96)
Loop diuretic 132 (93) 243 (81) 0.001
Nitroglycerin 29 (20) 86 (29) 0.06
Dobutamine 6 (4) 10 (3) 0.64
Dopamine 5 (4) 7 (2) 0.48
Data are reported as number (%). Groups are stratified based
on 5 point Likert Scale.
CPAP = continuous positive airway pressure.
Table 4A
Patient Characteristics Associated With Dyspnea Improvement
by Five-point Likert Scale
Variables AOR (95% CI) p-value
Baseline dyspnea
Very severely SOB 33.85 (9.43–121.52) <0.001
Severely SOB 7.61 (3.74–15.49) 0.45
Moderately SOB 5.79 (3.07–10.89) 0.77
Mildly SOB REF REF REF
Oxygen saturation 0.97 (0.92–1.03) 0.29
Preceding sign: fatigue 0.55 (0.30–0.99) 0.045
Jugular venous distention 0.48 (0.28–0.83) 0.009
New onset of heart
failure
0.99 (0.55–1.77) 0.97
Coronary artery disease 0.77 (0.45–1.33) 0.35
Chronic therapy: aspirin 0.60 (0.35–1.04) 0.07
Chest X-ray: pulmonary
edema
1.82 (0.88–3.75) 0.11
First ECG
Paced rhythm 0.36 (0.13–0.96) 0.041
Other abnormal
rhythm
0.47 (0.21–1.08) 0.076
IV loop diuretic use 0.41 (0.14–1.18) 0.10
Transdermal nitroglycerin
in the past 6 hours
0.35 (0.14–1.18) 0.048
N = 387; c-index = 0.831.
AOR = adjusted odds ratio; ECG = electrocardiogram; SOB =
short of breath.
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Dyspnea, or the sense of breathlessness, discomfits
patients, driving them to seek emergent care. Although
most patients improve during hospitalization, dyspnea
remains an unmet need for a sizable proportion of
patients despite early treatment. This lack of early bene-
fit has also been observed in a large clinical trial,
ASCEND-HF (Acute Study of Clinical Effectiveness of
Nesiritide in Decompensated Heart Failure), which used
a seven-point Likert scale.11 However, ASCEND-HF
enrolled patients up to 24 hours after presentation, in
contrast to our study, which enrolled patients within
1 hour of first physician evaluation. While other studies
using physician assessment suggests nearly all patients
improve,17 this study indicates that patient-assessed
dyspnea is not sufficiently relieved in many patients,
consistent with clinical trials where patients are enrolled
well after the ED phase of management, yet still have
dyspnea.8,18 Future trials targeting dyspnea may need
to enroll patients earlier to capture the majority of those
who experience early improvement.8,13 Patients who do
not improve significantly with early management may
represent a refractory or “hard-to-treat” group.
For each scale, we found unique clinical factors asso-
ciated with dyspnea improvement, suggesting that indi-
vidual scales may capture different aspects of the
patient’s reported symptoms. It was not our intent to
determine whether one scale is better than another, but
to better understand the similarities or differences in
regards to mapping patient characteristics. While inves-
tigators prefer a single, “best” scale, our study suggests
that use of multiple current scales may be required, as a
single scale may not accurately capture all AHF
patients. Based on our data, investigators might con-
sider use of a single scale if targeting a certain sub-
group of AHF with the patient characteristics most
associated with improvement or lack of improvement to
test whether interventions lead to changes in dyspnea
severity. More importantly, our findings suggest a com-
prehensive, validated patient-reported outcome of dysp-
nea improvement remains a critical unmet need in AHF
research.
Despite the prominence of dyspnea, trialists debate
its significance as a target.19 Perhaps such a relentless
focus on dyspnea has hindered other opportunities to
improve outcomes. Acute trials have, in general, not
defined or addressed other items important to patients,
such as functional capacity as primary endpoints.
Patients present with symptoms, however, and continue
to have significant symptoms despite early therapy. For
some HF patients, symptom improvement would be a
welcome trade for life-years. The less severe the symp-
toms, the less willing they are to trade survival time.20
Furthermore, failure to adequately relieve early symp-
toms in clinical trials has been associated with worse
30-day outcomes.4,11 However, these trials enrolled
patients relatively late in comparison to this analysis.
Further, these results assume that current dyspnea
assessments are correct. Although we defined “clinically
significant” dyspnea for our study, the minimal clinical
important difference has not been well studied, with a
study of 74 patients being the largest to date.15 It may
be the scale or use of the scale that is the issue, not the
symptom.
Further study of dyspnea and how to measure it is
warranted, given its prominence as a presenting symp-
tom and its association with worse outcomes. Standard-
ization of assessment remains important as divergent or
Figure 2. Patient characteristics associated with dyspnea
improvement for each assessment model. HF = heart failure.
Table 4B
Patient Characteristics Associated with Dyspnea Improvement
by VAS
Model
Scale Variables AOR 95% CI p-value
VAS Baseline dyspnea* 1.55 (1.36–1.77) <0.001
7-point
Likert
Jugular venous
distention
0.46 (0.28–0.77) 0.003
N = 311; c-index = 0.756
*For each one-point change by the VAS. Patients who could
not improve three points at baseline were excluded.
AOR = adjusted odds ratio; VAS = visual analog scale.
Table 4C
Patient Characteristics Associated With Dyspnea Improvement
by Seven-point Likert Scale
Variables AOR (95% CI) p-value
Dyspnea onset
Past 24 hours 2.00 (1.12–3.56) 0.31
1 to 3 days 1.45 (0.74–2.83) 0.66
3 to 5 days 2.35 (1.41–3.94) 0.044
>5 days REF REF REF
Peripheral edema 0.76 (0.49–1.19) 0.23
New onset of heart
failure
1.75 (1.12-.75) 0.014
Primary cardiomyopathy 0.51 (0.29–0.89) 0.019
Peripheral vascular
disease
3.40 (1.40–8.27) 0.007
Hypertension 1.51 (0.95–2.39) 0.08
Chest radiograph: normal 0.37 (0.10–1.40) 0.14
First ECG: other abnormal
rhythm
0.38 (0.18–0.78) 0.009
N = 476; c-index = 0.708.
AOR = adjusted odds ratio; ECG = electrocardiogram.
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different results based on type of dyspnea measurement
scale used raises questions about how to interpret study
results.
LIMITATIONS
This was a post hoc analysis, limited by the inability to
account for unmeasured confounders. Thus, our find-
ings are hypothesis-generating only. The inclusion and
exclusion criteria were broad, raising the possibility that
non-AHF patients were included. However, diagnostic
accuracy in the ED setting is relatively high, and natri-
uretic peptide levels provide additional support.21 Com-
pared to other AHF clinical trials, the number of
patients with AHF is relatively small. However, those
trials enrolled patients much later than this study.
Although the dyspnea scales used in this study have
been commonly used in AHF clinical trials, they have
not been rigorously validated according to established
standards for a patient-reported outcome. While the
scales do meet the face validity criterion, they have
largely been adapted from other settings, raising the
possibility that imprecision may have confounded our
results. The definition of improvement significantly
affects the results, with different thresholds likely to
yield differing associated patient characteristics. How-
ever, we used the definitions of dyspnea improvement
most commonly reported by other AHF trials and stud-
ies. The protocol did not mandate a specific order or
randomize the order of the three dyspnea assessment
scales. While that would have been ideal, practically this
would have required significantly more resources, as
this process would have been repeated several times.
While the majority of patients received intravenous
diuretic therapy, the lack of detailed doses for both
diuretics and vasodilators raises the possibility that un-
dertreatment may have an untoward effect. While
diuretics and nitrates do improve dyspnea in our analy-
sis, the fact that dyspnea improved in patients who did
not receive diuretics suggests potential confounding by
intention. As this was not a randomized trial design
originally, physicians may have chosen certain treat-
ments for reasons not captured by our study design.
CONCLUSIONS
Patients seek acute medical care when they feel short of
breath. Most acute heart failure patients report early
relief from dyspnea after initial therapy, but a sizable
number do not. Greater baseline dyspnea severity pre-
dicts early dyspnea improvement in the two scales
where baseline dyspnea was assessed. Variations in
patient characteristics associated with dyspnea
improvement were observed, depending on the type of
measurement instrument used. This, highlights the need
to better understand the symptom most responsible for
AHF hospital presentation, and to standardize its
assessment.
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